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Correspondence Clinical Evaluation of Losartan and Diltiazem
on the Development of T-Wave Memory by
Right Apical Ventricular PacingTo the Editor: It is known that a transient change in the sequence
of ventricular depolarization may be followed by inverted T waves
that become apparent once ventricular activation normalizes. In
1982, Rosenbaum et al. (1) coined this cumulative phenomenon
“cardiac memory,” as it occurs earlier if the ventricular myocar-
dium has been previously exposed to the same conditioning
stimulus. The most characteristic feature of “memory-induced”
T waves, better known as T-wave memory (TWM), is that their
spatial polarity tracks the direction of the conditioning QRS
complexes.
TWMs have been experimentally prevented by blockade of
either angiotensin I angiotensin receptors (ATIAR) or L-type
calcium channels (LCaCh) (2–4), suggesting that speciﬁc ion
channels and receptors are involved in the mechanism of TWM.
No information regarding the effect of these drugs on clinical
TWM is available.
We assessed the effects of losartan (ATIAR blocker) and dilti-
azem (LCaCh blocker) on induction of TWM in patients with
implanted pacemakers (PM).
Patients with sinus node dysfunction, normal atrioventricular
conduction, QRS, and T waves receiving a dual-chamber PM were
studied. Pacing was performed from the right ventricular apex.
After implantation, the devices were programmed to pace only the
atria (AAI) at 70/min. An electrocardiogram (ECG) was recorded
(C1) and repeated 1 week later (C2). Thereafter, the PM was
programmed DDD at 70/min with a short atrio-ventricular (A-V)
interval resulting in a fully paced QRS (C3). ECGs were repeated 1
(C4) and 2 (C5) weeks later during DDD and transient AAI
stimulation. Figure 1A shows an example of TWM. Then, the PM
was programmed to AAI and ECGs repeated at weekly intervals
until the T waves normalized. Patients were then randomized to
diltiazem (240 mg/day slow released) or losartan (50 mg twice a
day) during 3 weeks and the pacing protocol repeated (D2 to D5)
after 1 week of treatment.
An inverted protocol was performed in 8 patients treated for a
week with losartan (n ¼ 4) or diltiazem (n ¼ 4) and proceeding
from steps D2 to D5 during treatment. The protocol for TWM
induction was repeated to obtain baseline data.
The study protocol conformed to the principles outlined in the
Declaration of Helsinki and was approved by the Ethical Board of
Ramos Mejía Hospital.
Continuous variables between groups were compared with the
Mann-Whitney U test. The chi-square or Fisher exact tests were
used for categorical variables. Before and after diltiazem or losartan
administration, the T-wave axis on the frontal plane, the T-wave
amplitude (in lead III and in a precordial lead with most con-
spicuous TWM changes), and the QTc interval were compared
with the Wilcoxon signed rank test for nonparametric paired data.
A p value <0.05 was statistically signiﬁcant.Thirty of 42 patients in the study completed the protocol. The
mean age was 64.1  7.4 years (40% males). Before drug admin-
istration, the electrical axis of TWM shifted from þ30 to –60
(p < 0.001) (Fig. 1B). No statistical differences were observed with
losartan (from –60 to –60; p < 0.715) or diltiazem (from –55 to
–60; p < 0.334). TWM polarity and amplitude were not modiﬁed
by losartan or diltiazem (Fig. 1C).
Induction of TWM caused a small prolongation of QTc in-
terval at baseline, from 0.42 to 0.43 s (p ¼ 0.002), and also during
both losartan, from 0.42 to 0.43 s (p ¼ 0.008), and diltiazem,
from 0.42 to 0.43 s (p ¼ 0.022). Similar TWM changes were
obtained in 8 patients already receiving losartan or diltiazem
before initiating right ventricular apical pacing (RVAP).
The present study demonstrates that losartan and diltiazem do
not modify the TWM induced by RVAP, in contrast to experi-
mental observations. The reasons for these dissimilar results are not
readily apparent.
TWM appears as a benign electrical remodeling, although it
shares transduction pathways with factors that may be pathological,
such as angiotensin II and reactive oxygen species. TWM in
patients denotes that pacing evokes regional changes in the repo-
larization process depending on electrotonic inﬂuence of sur-
rounding tissues and activation time of ventricular myocardium.
During RVAP, activation departs from the right ventricular apex
and ends in the basal left ventricle causing depolarizing forces
oriented posteriorly and leftward. Repolarization lengthens in the
apex but shortens at the base. Once normal activation resumes,
negative T waves appear in the ECG leads in which the paced QRS
complexes had been negative, signaling an important change in the
repolarization gradient (5). TWM may be due to regional
stretching of cardiomyocytes (4,6), leading to increased synthesis
and liberation of angiotensin II causing augmented trafﬁcking and
internalization of a complex composed by the ATIAR and the
potassium-channel protein KV4,3/KChIP2CH and an increment
in the calcium current ICaL. The cAMP response element binding
is reduced in ventricular myocardium of dogs undergoing 2 h
ventricular pacing and saralasin (ATIAR blocker) and nifedipine
(LCaCh blocker) prevented this effect (7). This could impede
changes in the density of Ito, IKr, and ICaL currents thought to play
a major role in TWM. Ventricular pacing also leads to myocardial
angiotensin II production and to proteosomal degradation of
cAMP response element binding (8) and the downstream ion
channel changes involved in the onset of long-term TWM.
Based on experimental data we hypothesized that in our clinical
model, TWM could be prevented by losartan and/or diltiazem
administration. This assumption was not conﬁrmed by our results
although the small sample size is a limitation. Further studies are
necessary to determine whether faster or longer periods of RVAP
may modify the results.
Figure 1 Memory-Induced T-Wave Changes by RVAP at Baseline and Under Treatment With Losartan or Diltiazem
(A) Induction of typical T-wave memory (TWM) changes in 1 of the patients. Interruption of a 2-week period of right ventricular apical pacing (RVAP) caused inverted T waves in
leads where the paced QRS complex had been negative. (B) Absence of changes in the mean T-wave electrical axis after induction of TWM in control conditions and under the
effects of losartan and diltiazem. (C) Changes in T-wave polarity and voltage induced by a 2-week period of ventricular pacing in leads III and V4 at baseline and during losartan
and diltiazem administration. TWM changes were not modiﬁed by these agents. AP ¼ atrial pacing only (AAI mode).
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1930The results of our study suggest that the mechanisms involved in
clinical TWM may be more complex than previously recognized
under experimental conditions.*Pablo A. Chiale, MDy
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Rhythm 2010;7:964–70.Letters to the EditorSudden Death in
Adolescent Athletes
The recent report based on data from the Minnesota State High
School League (MSHSL) is deserving of additional comment.
Lawless (1) and Roberts and Stovitz (2) suggest that the incidence
of sudden cardiac death is far lower than that reported elsewhere,
and, therefore, additional electrocardiographic screening is unwar-
ranted and would produce little added value. That this evaluation
was accomplished with the same database as has been previously
queried by others with different results and is at variance with other
reports is no surprise given the methods (3–5).
Unfortunately, the 4 “during participation deaths” over 20 years
of study do not include athletes successfully resuscitated (n ¼ 8) or
not involved in sports participation at the time of sudden death
(n ¼ 7) or those whose deaths were not reported to the League or
insurers. In this study, there were no less than 19 sudden death
episodes recorded, the majority of which occurred outside the few
hours per week of sports exposure. No data are available as to the
sudden death episodes that would not have been captured by this
database, such as the number of unexplained or sudden deaths or
successful resuscitations in this population in Minnesota during the
same time period. Thus, the numerator in the calculation of inci-
dence of cardiac death in high school athletes may be severely
underestimated. Likewise, the denominator is overestimated by
applying it to all students rather than screened athletes, and the
number of athlete-years is an estimate (approved participation in a
sport does not mean that participation in that sport actually took
place). As a result, estimates of the incidence of sudden death in
this population are markedly understated, and any conclusions
regarding the value of an electrocardiogram are speculative at best.
In reﬁning the pre-participation evaluation, we must consider
that its purpose is to prevent sudden death in athletes in whom a
long and relatively healthy life could otherwise be anticipated and to
afford those at risk appropriate evaluation and therapy. The goal is
not merely to prevent sudden death on the ﬁeld but sudden death at
any time. A small percentage of adolescents die each year withhearts that could support them for many years if they could have
been treated through the acute period of compromise (6). Pre-
venting the loss of decades of life should stimulate creation of a
registry in which all pertinent data are recorded. Such a database
should include outcomes of screening (e.g., reasons for failure,
recommendations, and outcomes) and permit us to further improve
the health of our young citizens. Reliance on National Collegiate
Athletic Association databases, public media reports, and cata-
strophic insurance claims is inadequate.
We need to determine whether we can further reduce the risk of
sudden death in adolescents. If indeed a reduction of such deaths by
virtue of better screening techniques and availability of automated
external devices has occurred, it should be shown in appropriate eval-
uation of the data. It does appear from the Minnesota experience that
we have improved our care sufﬁciently to report more resuscitations
than deaths on the ﬁeld and that screening may have provided the
impetus for further evaluation and treatment in those at risk.*Larry A. Weinrauch, MD
*Harvard Medical School





1. Lawless CE. Minnesota High School athletes 1993–2012: evidence that
American screening strategies and sideline preparedness are associated
with very low rates of sudden cardiac deaths. J Am Coll Cardiol 2013;62:
1302–3.
2. Roberts WO, Stovitz SD. Incidence of sudden cardiac death in Min-
nesota high school athletes 1993-2012 screened with a standardized pre-
participation evaluation. J Am Coll Cardiol 2013;62:1298–301.
3. Maron BJ, Haas T, Ahluwalia A, Rutten-Ramos SC. Incidence of
cardiovascular sudden deaths in Minnesota high school athletes. Heart
Rhythm 2013;10:374–7.
4. Maron BJ, Haas TS, Doerer JJ, Thompson PD, Hodges JS. Comparison
of US and Italian experiences with sudden cardiac deaths in young
competitive athletes and implications for preparticipation screening
strategies. Am J Cardiol 2009;104:276–80.
5. Harmon KG, Asif IM, Klossner D, Drezner JA. Incidence of sudden
cardiac death in National Collegiate Athletic Association athletes. Cir-
culation 2011;123:1594–600.
6. Drezner JA, Toresdahl BG, Rao AL, Huszti E, Harmon KG. Outcomes
from sudden cardiac arrest in US high schools: a 2-year prospective study
from the National registry for AED Use in Sports. Br J Sports Med
2013;47:1179–83.ReplySudden Death in
Adolescent Athletes
We thank Dr. Weinrauch for highlighting the complexity of
obtaining accurate assessments of sudden cardiac death (SCD)
rates in sports.
As we stated, the number of SCDs used in our calculations
(i.e., the numerator) “does not include athletes who experienced a
